The results met its 1EP and showed a significant improvement in OS for the P-III study, evaluating Tumor Treating Fields + ICI/docetaxel (experimental arm) vs ICI/docetaxel alone (control arm) for stage 4 NSCLC following progression while on or after treatment with platinum-based therapy
Superior OS of patients treated with TTFields + ICI vs ICI alone & TTFields + docetaxel vs docetaxel alone are being evaluated as the 2EPs
Additionally, the company plans to present complete results in an upcoming medical conference and in H2’23 plans to file PMA and CE mark to the US FDA and the EU, respectively
Ref: Novocure | Image: Novocure
Related News:- MSD Collaborates with Novocure to Evaluate Tumor Treating Fields Together with Keytruda (pembrolizumab) in Non-Small Cell Lung Cancer
